Biostatistics

Applications in Medicine

Syllabus

1. General review

- a. What is Biostatistics?
- b. Population/Sample/Sample size
- c. Type of Data quantitative and qualitative variables
- d. Common probability distributions
- e. Work example Malaria in Tanzania

2. Applications in Medicine

- a. Construction and analysis of diagnostic tools Binomial distribution, sensitivity, specificity, ROC curve,Rogal-Gladen estimator
- b. Estimation of treatment effects generalized linear models
- c. Survival analysis Kaplan-Meier curve, log-rank test, Cox's proportional hazards model

3. Applications in Genetics, Genomics, and other 'omics data

- Genetic association studies Hardy-Weinberg test, homozygosity, minor allele frequencies, additive model, multiple testing correction
- b. Methylation association studies M versus beta values, estimation of biological age
- c. Gene expression studies based on RNA-seq experiments Tests based on Poisson and Negative-Binomial

4. Other Topics

- a. Estimation of Species diversity Diversity indexes, Poisson mixture models
- b. Serological analysis Gaussian (skew-normal) mixture models
- c. Advanced sample size and power calculations

Accuracy Parsimony

The art of statistical modelling

Multicollinearity Interpretability

Generalisation

The art of constructing a model

Select the best link function

Fit models with different link functions and compare them

Select the best subset of covariates (feature selection)

Forward/Backward/Stepwise Regression

Penalised regression (LASSO or Elastic-Net)

Classical model comparison and selection

AIC - Akaike's Information Criterion

BIC - Bayesian Information Criterion

AIC (M) =
$$(-2)\log\text{-L}(\hat{\theta} \mid M, \mathbf{x}) + 2p$$

BIC (M) =
$$(-2)\log\text{-L}(\hat{\theta}|M,\mathbf{x}) + p\log(n)$$

 $\log - L(\hat{\theta} | M, \mathbf{x})$ is the log-likelihood function evaluated on the parameter estimates

p is the number of parameters of model M

n is the sample size

Choose the model with the lowest values of one of these measures

Forward selection

"Empty" Model

Stop procedure

Add covariate
Add covariate
Add covariate
Add covariate

Increased accuracy compensates
increased model complexity

Increased accuracy does not compensate

increased model complexity

Backward elimination

"All covariates" Model

Remove covariate

Remove covariate

Remove covariate

Stop procedure

Decreased model complexity does not have an impact on model accuracy

Decreased model complexity has an impact on model accuracy

Stepwise regression

"Empty" Model

Add covariate 1

Add covariate 2 Remove covariate 1

Add covariate 3 Remove covariates 1, 2 Increased accuracy compensates increased model complexity

Stop procedure

Increased accuracy does not compensate increased model complexity

Stepwise regression

Advantages

Remove multicolinearity

Easy automation

Speed

Disadvantages

Overestimation of the number of predictors

Inflated type I errors

Unstable to slight changes in the data

Exercise:

Covariates: Age, Gender, Infection trigger, Disease Duration

Use logit, probit, cloglog, loglog, cauchit.

Compare models/Use a feature selection strategy



RESEARCH ARTICLE

B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment

Øystein Fluge¹*, Kristin Risa¹, Sigrid Lunde¹, Kine Alme¹, Ingrid Gurvin Rekeland¹, Dipak Sapkota^{1,2}, Einar Kleboe Kristoffersen^{3,4}, Kari Sørland¹, Ove Bruland^{1,5}, Olav Dahl^{1,4}, Olav Mella^{1,4}*


- 1 Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway,
- 2 Department of Clinical Medicine, University of Bergen, Haukeland University Hospital, Bergen, Norway,
- 3 Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway,
- 4 Department of Clinical Science, University of Bergen, Haukeland University Hospital, Bergen, Norway,
- 5 Department of Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway

Packages ordinal, glmx, and MASS

What will be your final model to understand the effect of treatment better?



Penalised regression





Penalised regression

$$\hat{\mathbf{b}} = \underset{\mathbf{b}}{\operatorname{argmin}} \left\{ \sum_{i=1}^{n} \left(y_i - b_0 - \sum_{j=1}^{p} b_j x_i \right)^2 \right\}.$$

subject to a constraint

$$pen \leq \lambda$$

$$\lambda$$
 = tuning parameter

Ridge Regression

$$\hat{\boldsymbol{b}} = \underset{\boldsymbol{b}}{\operatorname{argmin}} \left\{ \sum_{i=1}^{n} \left(y_i - b_0 - \sum_{j=1}^{p} b_j x_i \right)^2 \right\},\,$$

subject to
$$\sum_{j=1}^{p} b_j^2 \le \lambda_2$$

$$\lambda_2 \in \left[0, \sum_{j=1}^p (\hat{b}_j^*)^2\right]$$

OLS estimates

Geometrical interpretation (2D)

$$\sum_{j=1}^{2} b_j^2 \le \lambda_2$$

$$b_1 = r \cos \theta$$


$$b_2 = r \sin \theta$$

$$r^2(\cos^2\theta + \sin^2\theta) \le \lambda_2$$

$$r^2 \leq \lambda_2$$

Ridge estimator is only dependent on the radius and not on the angle

Geometrical interpretation (2D)



Ordinary least squares estimator

$$\hat{\mathbf{b}} = (\mathbf{X}^T \mathbf{X})^{-1} \mathbf{X}^T \mathbf{Y}$$

Ridge estimator

$$\hat{\mathbf{b}} = (\mathbf{X}^T \mathbf{X} + \lambda_2 \mathbf{I})^{-1} \mathbf{X}^T \mathbf{Y}$$

Ridge Regression


$$\hat{\boldsymbol{b}} = \underset{\boldsymbol{b}}{\operatorname{argmin}} \left\{ \sum_{i=1}^{n} \left(y_i - b_0 - \sum_{j=1}^{p} b_j x_i \right)^2 \right\},\,$$

subject to
$$\frac{\sum_{j=1}^p b_j^2}{\sum_{j=1}^p (\hat{b}_j^*)^2} \leq 1 - \lambda^*$$

0% shrinkage

$$\lambda^* \in [0,1]$$
"100%" shrinkage

Ridge trace plot



Ridge regression

Advantages

Disadvantages

Remove multicollinearity

Biased estimators

Estimator with a closed form

No shrinkage to zero

Shrinkage

(No model selection)

LASSO Regression

$$\hat{\mathbf{b}} = \underset{\mathbf{b}}{\operatorname{argmin}} \left\{ \sum_{i=1}^{n} \left(y_i - b_0 - \sum_{j=1}^{p} b_j x_i \right)^2 \right\},\,$$

subject to
$$\sum_{j=1}^{p} |b_j| \le \lambda_1$$

$$\lambda_1 \in \left[0, \sum_{j=1}^p |\hat{b}_j^*|\right]$$

OLS estimates

Geometrical interpretation (2D)

$$\sum_{j=1}^{2} |b_j| \le \lambda_1$$

$$b_1 = r \cos \theta$$


$$b_2 = r\sin\theta$$

$$r(\cos\theta + \sin\theta) \le \lambda_2$$

$$r^2 \leq \lambda_2$$

LASSO estimator is dependent on both radius and angle

Geometrical interpretation (2D)




LASSO Regression


$$\hat{\mathbf{b}} = \underset{\mathbf{b}}{\operatorname{argmin}} \left\{ \sum_{i=1}^{n} \left(y_i - b_0 - \sum_{j=1}^{p} b_j x_i \right)^2 \right\} ,$$

subject to
$$\frac{\sum_{j=1}^{p}|b_{j}|}{\sum_{j=1}^{p}|b_{j}^{*}|} \leq 1 - \lambda^{*}$$

0% shrinkage (OLS)



LASSO trace plot



LASSO regression

Advantages

Remove multicollinearity

Shrinkage to zero

(Model selection)

Disadvantages

Random choice of highly correlated covariates

No closed-form expression

Problems with standard errors

Elastic Net Regression

$$\hat{\mathbf{b}} = \underset{\mathbf{b}}{\operatorname{argmin}} \left\{ \sum_{i=1}^{n} \left(y_i - b_0 - \sum_{j=1}^{p} b_j x_i \right)^2 \right\} ,$$

subject to
$$\alpha |\mathbf{b}|_1 + (1 - \alpha) |\mathbf{b}|^2 \le \lambda$$
 for some λ and $\alpha \in [0,1]$.

$$\alpha = 0 \Rightarrow$$
 Ridge regression

$$\alpha = 1 \Rightarrow LASSO$$
 regression


Estimation of the tuning parameter(s)

Evaluate a grid of possible values


Highest Cross-validation

Lowest mean squared error


Example: Ridge Regression



Example: LASSO Regression



Example: Elastic Net Regression



Exercise:

Covariates: Age, Gender, Infection trigger, Disease Duration

Use a binomial model with the probit function

Use LASSO regression



RESEARCH ARTICLE

B-Lymphocyte Depletion in Myalgic Encephalopathy/ Chronic Fatigue Syndrome. An Open-Label Phase II Study with Rituximab Maintenance Treatment

Øystein Fluge¹*, Kristin Risa¹, Sigrid Lunde¹, Kine Alme¹, Ingrid Gurvin Rekeland¹, Dipak Sapkota^{1,2}, Einar Kleboe Kristoffersen^{3,4}, Kari Sørland¹, Ove Bruland^{1,5}, Olav Dahl^{1,4}, Olav Mella^{1,4}*

- 1 Department of Oncology and Medical Physics, Haukeland University Hospital, Bergen, Norway,
- 2 Department of Clinical Medicine, University of Bergen, Haukeland University Hospital, Bergen, Norway,
- 3 Department of Immunology and Transfusion Medicine, Haukeland University Hospital, Bergen, Norway,
- 4 Department of Clinical Science, University of Bergen, Haukeland University Hospital, Bergen, Norway,
- 5 Department of Medical Genetics and Molecular Medicine, Haukeland University Hospital, Bergen, Norway

Package glmnet

What will be the final model to understand the effect of treatment better?



Syllabus

1. General review

- a. What is Biostatistics?
- b. Population/Sample/Sample size
- c. Type of Data quantitative and qualitative variables
- d. Common probability distributions
- e. Work example Malaria in Tanzania

2. Applications in Medicine


- a. Construction and analysis of diagnostic tools Binomial distribution, sensitivity, specificity, ROC curve,Rogal-Gladen estimator
- b. Estimation of treatment effects generalized linear models
- c. Survival analysis Kaplan-Meier curve, log-rank test, Cox's proportional hazards model

3. Applications in Genetics, Genomics, and other 'omics data

- Genetic association studies Hardy-Weinberg test, homozygosity, minor allele frequencies, additive model, multiple testing correction
- b. Methylation association studies M versus beta values, estimation of biological age
- c. Gene expression studies based on RNA-seq experiments Tests based on Poisson and Negative-Binomial

4. Other Topics

- a. Estimation of Species diversity Diversity indexes, Poisson mixture models
- b. Serological analysis Gaussian (skew-normal) mixture models
- c. Advanced sample size and power calculations



Develop

Survival or time-to-event analysis



Endpoint: time to event

Examples of endpoints

time to death in cancer patients (hence, survival analysis)

time to first symptomatic infection after vaccination

time to hospital discharge

time to a positive diagnosis of a chronic disease

time to clearance of infection

What parametric distributions could be used to analyse this random variable?

T = random variable that represents the time when the event of interest occurs

$$T \rightsquigarrow ?$$

Survival function


$$S(t) = P(T > t), \ t \ge 0$$

$$S(t) = 1 - F(t), \ t \ge 0$$

S is strictly a decreasing (continuous) function

$$S(0) = 1$$
 and $S(+\infty) = 0$

Example



Hazard function (formal definition)

$$h(t) = \lim_{dt \to 0+} \frac{P[t \le T < t + dt \mid T \ge t]}{dt}$$

"Instant" risk of the event occurring at time t

Hazard function (more practical definition)

$$h(t) = \frac{f(t)}{S(t)}$$

Hazard function is simply the ratio between the probability density function and the survival function

Two interesting relationships between probability density function, survival function and hazard function

$$f(t) = \lim_{dt \to 0+} \frac{P[t \le T < t + dt]}{dt} = -S'(t)$$

$$h(t) = -\frac{S'(t)}{S(t)} \Leftrightarrow S(t) = e^{-\int_0^t h(x)dx}$$

(by the fundamental theorem of calculus)

Exercise 0

Use the practical definition of hazard function and plot the hazard functions of the following distributions:

Exponential distribution with rate parameter =1

Gamma distribution with shape parameter = 0.5 and rate parameter = 1

Gamma distribution with shape parameter = 1.5 and rate parameter = 1

What is your interpretation of these hazard functions?

Discussion

What is the qualitative aspect of the hazard function for time to death in humans?

Exercise 1: data about recovery from a SARS-CoV-2 infection

16 patients from a Beijing hospital between January 28 and February 9, 2020

time to end of symptoms

time to negative PCR test

Package MASS

Fit exponential, gamma, lognormal, and weibull distributions to each endpoint

Select the best model to each endpoint and plot the corresponding survival and hazard functions

Draw your conclusions

Chang D, Mo G, Yuan X, et al. Time Kinetics of Viral Clearance and Resolution of Symptoms in Novel Coronavirus Infection. Am J Respir Crit Care Med. 2020;201(9):1150-1152.